Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 2/13/2025 | $38.00 | Buy | UBS |
| 12/6/2024 | $63.00 | Outperform | BMO Capital Markets |
| 9/9/2024 | $70.00 | Mkt Outperform | JMP Securities |
| 7/8/2024 | $90.00 | Buy | BTIG Research |
| 6/27/2024 | $86.00 | Buy | Stifel |
| 5/6/2024 | $65.00 | Buy | H.C. Wainwright |
| 4/3/2024 | $65.00 | Outperform | Evercore ISI |
| 3/28/2024 | $70.00 | Outperform | RBC Capital Mkts |
REDWOOD CITY, Calif., Feb. 10, 2025 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (NASDAQ:JSPR) (Jasper), a clinical stage biotechnology company focused on development of briquilimab, a novel antibody therapy targeting c-Kit (CD117) to address mast cell driven diseases such as chronic spontaneous urticaria (CSU), chronic inducible urticaria (CIndU) and asthma, today announced five poster presentations and an oral presentation of briquilimab data at the AAAAI 2025 Annual Meeting, being held February 28 - March 3, 2025, in San Diego, CA. The oral presentation and one of the poster presentations will include additional follow-up from patients included in the Company's January 8th, 2025, discl
REDWOOD CITY, Calif., Feb. 04, 2025 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (NASDAQ:JSPR) (Jasper), a clinical stage biotechnology company focused on development of briquilimab, a novel antibody therapy targeting c-Kit (CD117) to address mast cell driven diseases such as chronic spontaneous urticaria (CSU), chronic inducible urticaria (CIndU) and asthma, today announced that its management will present at the Oppenheimer Healthcare Life Sciences Conference, taking place February 11-12, 2025. Oppenheimer Healthcare Life Sciences ConferencePresentation Date/Time: Tuesday, February 11, 2025; 3:20 p.m. ESTPresentation Format: Fireside Chat A live webcast of the presentation will be ava
Rapid onset of deep and durable clinical responses observed across multiple dosing cohorts with a favorable safety profile Mean change in UAS7 from baseline of -26.6 observed in the 240mg single dose cohort at 8 weeks, multiple dosing regimens ≥120mg demonstrated UAS7 change of more than -25 points 100% (N=3) Complete Responses (UAS7 = 0) observed in the 240mg single dose cohort at 8 weeks and 66% maintained Well Controlled disease at 12 weeks Serum tryptase reductions below the lower limit of quantification observed at multiple dose levels Data supports commencement of CSU registrational program expected to commence second half of 2025 Company t
UBS initiated coverage of Jasper Therapeutics with a rating of Buy and set a new price target of $38.00
BMO Capital Markets initiated coverage of Jasper Therapeutics with a rating of Outperform and set a new price target of $63.00
JMP Securities initiated coverage of Jasper Therapeutics with a rating of Mkt Outperform and set a new price target of $70.00
4 - Jasper Therapeutics, Inc. (0001788028) (Issuer)
4 - Jasper Therapeutics, Inc. (0001788028) (Issuer)
4 - Jasper Therapeutics, Inc. (0001788028) (Issuer)
REDWOOD CITY, Calif., June 19, 2024 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (NASDAQ:JSPR) (Jasper), a clinical stage biotechnology company focused on development of briquilimab, a novel antibody therapy targeting c-Kit (CD117) to address mast cell driven diseases such as chronic spontaneous urticaria (CSU), chronic inducible urticaria (CIndU) and asthma, today announced the appointment of Svetlana Lucas, Ph.D., to Jasper's Board of Directors (the Board), effective as of June 18, 2024. Separately, Anna French, D. Phil., stepped down from the Board, effective as of June 18, 2024. "We are pleased to welcome Svetlana, an experienced and accomplished biopharmaceutical executive, to our B
REDWOOD CITY, Calif., Nov. 01, 2023 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (NASDAQ:JSPR) (Jasper), a biotechnology company focused on the development of briquilimab, a novel antibody therapy targeting c-Kit (CD117) to address mast cell driven diseases such as chronic spontaneous urticaria (CSU) and chronic inducible urticaria (CIndU), as well as lower to intermediate risk myelodysplastic syndromes (LR-MDS) and novel stem cell transplant conditioning regimens, today announced the appointment of Thomas G. Wiggans, a veteran biopharmaceutical executive, as Chairperson of Jasper's Board of Directors (the Board), effective immediately. Bill Lis is stepping down as Chairperson and will re
Patricia Carlos Appointed Senior Vice President of Regulatory Affairs and Quality Annette Marcantonio Appointed Vice President of Clinical Operations REDWOOD CITY, Calif., Aug. 02, 2023 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (NASDAQ:JSPR) (Jasper), a biotechnology company focused on the development of briquilimab, a novel antibody therapy targeting c-Kit (CD117) to address diseases such as chronic spontaneous urticaria (CSU), lower to intermediate risk myelodysplastic syndromes (LR-MDS) as well as novel stem cell transplant conditioning regimes, today announced the appointment of two seasoned pharma industry executives to its regulatory affairs, quality and clinical operations
8-K - Jasper Therapeutics, Inc. (0001788028) (Filer)
8-K - Jasper Therapeutics, Inc. (0001788028) (Filer)
10-Q - Jasper Therapeutics, Inc. (0001788028) (Filer)
Rapid onset of deep and durable clinical responses observed across multiple dosing cohorts with a favorable safety profile Mean change in UAS7 from baseline of -26.6 observed in the 240mg single dose cohort at 8 weeks, multiple dosing regimens ≥120mg demonstrated UAS7 change of more than -25 points 100% (N=3) Complete Responses (UAS7 = 0) observed in the 240mg single dose cohort at 8 weeks and 66% maintained Well Controlled disease at 12 weeks Serum tryptase reductions below the lower limit of quantification observed at multiple dose levels Data supports commencement of CSU registrational program expected to commence second half of 2025 Company t
14 of 15 participants enrolled achieved a clinical response 10 of 12 participants in the 120mg cohort achieved a complete response No serious adverse events; no grade 3 or higher adverse events reported Initial data from BEACON study expected week of January 6th, 2025, including 180mg Q8W cohort Company to host conference call and webinar today at 8:00 a.m. EDT REDWOOD CITY, Calif., Oct. 14, 2024 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (NASDAQ:JSPR) (Jasper), a clinical stage biotechnology company focused on development of briquilimab, a novel antibody therapy targeting c-Kit (CD117) to address mast cell driven diseases such as chronic spontaneous urticaria (CSU), chronic induci
SC 13G/A - Jasper Therapeutics, Inc. (0001788028) (Subject)
SC 13G/A - Jasper Therapeutics, Inc. (0001788028) (Subject)
SC 13G/A - Jasper Therapeutics, Inc. (0001788028) (Subject)
4 - Jasper Therapeutics, Inc. (0001788028) (Issuer)
4 - Jasper Therapeutics, Inc. (0001788028) (Issuer)
4 - Jasper Therapeutics, Inc. (0001788028) (Issuer)